Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02162953 · ClinicalTrials.gov registry record
Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.
A clinical trial of Retinal Disease and Best Vitelliform Macular Dystrophy, sponsored by Mayo Clinic.
- Completed
- Registry status
- 48
- Enrollment target
- 1
- Study location
NCT02162953 is a study of Retinal Disease and Best Vitelliform Macular Dystrophy that has completed, run by Mayo Clinic. The registered enrollment target is 48 participants, below the 1,239-participant average among 19 other Retinal Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02162953, a study of Retinal Disease and Best Vitelliform Macular Dystrophy, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Autosomal recessive bestrophinopathy (ARB) is one of 5 blinding eye diseases caused by mutations in the gene BEST1. These diseases, collectively termed "bestrophinopathies" include ARB, Best vitelliform macular dystrophy (BVMD), adult-onset vitelliform dystrophy (AVMD), autosomal dominant vitreoretinalchoroidopathy (ADVIRC) and retinitis pigmentosa (RP) . Objective: To collect DNA/RNA and skin samples from individuals with ARB or other diseases due to mutations in the gene BEST1. These models will be used to identify and test therapeutic approaches to treating these diseases. Design: Study involves a one time donation of a skin punch biopsy and whole blood. Once the skin biopsy is obtained, skin fibroblasts will be isolated, which will be reprogrammed into iPSCs. RPE cells will be derived from the iPSCs
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-02 |
| Est. Completion | 2022-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02162953
The ClinicalTrials.gov registry entry for NCT02162953 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,239-participant average among 19 other Retinal Disease trials with a reported enrollment target (96% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Retinal Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02162953 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02162953 about?
NCT02162953 is a clinical study titled "Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.". Background: Autosomal recessive bestrophinopathy (ARB) is one of 5 blinding eye diseases caused by mutations in the gene BEST1. These diseases, collectively termed "bestrophinopathies" include ARB, Best vitelliform macular dystrophy (BVMD), adult-onset vitelliform dystrophy (AVMD), autosomal dominan...
What is the current status of trial NCT02162953?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2014-02. Estimated completion is 2022-12-31.
What conditions does trial NCT02162953 study?
This clinical trial studies the following conditions: Retinal Disease, Best Vitelliform Macular Dystrophy, Bestrophinopathy, Adult Onset Vitelliform Macular Dystrophy, Autosomal Dominant Vitreoretinalchoroidopathy.
Who is sponsoring clinical trial NCT02162953?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02162953 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
RECRUITING · Phase 3
-
Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene
RECRUITING
-
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease
RECRUITING · NA
-
P200TxE Diseased Eye Image Collection
RECRUITING · NA
-
Data Gathering for A10900
RECRUITING
-
Inherited Retinal Degenerative Disease Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.